<p>OraSure Technologies（纳斯达克：OSUR - 获取免费报告）于周三发布了其财报。这家医疗仪器供应商报告本季度每股收益为（$0.21），低于分析师一致预期的（$0.17），差距为（$0.04），据 Zacks 报道。OraSure Technologies 的股本回报率为负 13.61%，净利润率为负 47.92%。</p>
<p>获取 <strong>OraSure Technologies</strong> 的提醒：</p>
<p>以下是 OraSure Technologies 电话会议的关键要点：</p>
<ul>
<li>在 12 月提交了两个 FDA 申请，针对衣原体/淋病的快速分子 OTC 自测（Sherlock）和 <strong>Colli-Pee</strong> 家庭尿液采集设备，目标是在年中推出，并在 2026 年下半年实现收入增长；管理层提到 CT/NG 的市场总值超过 15 亿美元。</li>
<li>国际诊断趋势正在稳定，OTI 正在追求 <strong>近岸外包</strong>（在非洲本地组装）并整合 BioMedomics，以扩大 <strong>Sickle SCAN</strong> 测试的分销，预计从第一季度开始贡献收入，并持续到 2026 年。</li>
<li>第四季度收入为 2680 万美元（核心收入 2670 万美元），高于中间指导，GAAP 毛利率改善至 41%；公司在 2025 年结束时现金为 1.99 亿美元，无债务，回购 1500 万美元，但报告 GAAP 营业亏损为 2010 万美元，经营现金流为负，预计第一季度收入为 2600 万至 2900 万美元，并预计到 2027 年实现经营现金流持平。</li>
<li>运营措施——制造整合到贝塞勒姆，内部化合同量，以及随着临床试验结束研发支出的预期下降——应推动随着收入增长而提高的顺序毛利率。</li>
</ul>
<h2>OraSure Technologies 价格表现</h2>
<p>周三中午交易时，纳斯达克 OSUR 下跌 0.02 美元，达到 2.80 美元。该股票的交易量为 539,717 股，而其平均交易量为 505,879 股。该公司的市值为 2.0084 亿美元，市盈率为-3.50，贝塔值为 0.87。OraSure Technologies 的 1 年最低价为 2.08 美元，1 年最高价为 4.22 美元。该公司的 50 日移动平均价格为 2.65 美元，200 日移动平均价格为 2.79 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对该公司的持股。西北互助财富管理公司在第四季度将其在 OraSure Technologies 的股份提高了 12,890.9%。西北互助财富管理公司现在拥有 49,755 股该医疗仪器供应商的股票，价值 120,000 美元，此前在此期间又收购了 49,372 股。拉塞尔投资集团在第四季度将其在 OraSure Technologies 的股份增加了 13.3%。拉塞尔投资集团现在拥有 43,636 股该医疗仪器供应商的股票，价值 106,000 美元，此前在此期间又收购了 5,138 股。Sei Investments Co.在第三季度将其在 OraSure Technologies 的股份提高了 16.4%。Sei Investments Co.现在拥有 32,244 股该医疗仪器供应商的股票，价值 103,000 美元，此前在上个季度又购买了 4,536 股。Numerai GP LLC 在第四季度购买了 OraSure Technologies 的新头寸，价值约 100,000 美元。最后，Envestnet 资产管理公司在第二季度将其在 OraSure Technologies 的持股提高了 32.7%。Envestnet 资产管理公司现在拥有 33,018 股该医疗仪器供应商的股票，价值 99,000 美元，此前在此期间又购买了 8,133 股。对冲基金和其他机构投资者持有该公司 93.50% 的股票。</p>
<h2>分析师评级变动</h2>
<p>一些券商对 OSUR 发表了看法。斯蒂芬斯在 11 月 12 日的研究报告中将 OraSure Technologies 的目标股价从 3.50 美元下调至 3.00 美元，并对该公司设定了 “持平” 评级。韦斯评级在 1 月 22 日的研究报告中重申了对 OraSure Technologies 的 “卖出（d）” 评级。两位分析师对该股票给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，OraSure Technologies 目前的共识评级为 “减持”，平均目标价为 3.00 美元。</p>
<p><strong>查看我们关于 OSUR 的最新报告</strong></p>
<h2>OraSure Technologies 公司简介</h2>
<p>（获取免费报告）</p>
<p>OraSure Technologies, Inc 是一家位于宾夕法尼亚州贝塞勒姆的诊断和医疗设备公司，专注于开发、制造和商业化即时检测和自我检测产品。成立于 1988 年，OraSure 建立了一系列口腔液体和其他非侵入性样本采集技术，支持传染病、药物滥用和健康与保健生物标志物的检测。</p>
<p>该公司的旗舰产品 OraQuick®快速 HIV 测试是首个获得食品和药物管理局批准的非处方口腔液体 HIV-1/2 抗体检测。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 OraSure Technologies</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>这让我感到愤怒</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1NVUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1NVUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 OraSure Technologies 吗？</h2>
<p>在你考虑 OraSure Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 OraSure Technologies 并不在名单上。</p>
<p>虽然 OraSure Technologies 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

奥瑞许科技

<p>奥瑞许科技 (NASDAQ:OSUR) 报告的季度每股收益为（$0.21），低于预期 $0.04。该公司的净利润率为负 47.92%，股本回报率为 -13.61%。尽管第四季度收入为 2680 万美元，奥瑞许预计到 2027 年将实现经营现金流平衡。该股交易价格下跌至 $2.80，市值为 2.0084 亿美元。分析师已将目标价格下调至 $3.00，普遍评级为 “减持”</p>

<p>OraSure Technologies (NASDAQ:OSUR - Get Free Report) released its earnings results on Wednesday. The medical instruments supplier reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04), Zacks reports. OraSure Technologies had a negative return on equity of 13.61% and a negative net margin of 47.92%.</p>
<div class="lb-trans"><p>OraSure Technologies（纳斯达克：OSUR - 获取免费报告）于周三发布了其财报。这家医疗仪器供应商报告本季度每股收益为（$0.21），低于分析师一致预期的（$0.17），差距为（$0.04），据 Zacks 报道。OraSure Technologies 的股本回报率为负 13.61%，净利润率为负 47.92%。</p>
</div><p>Get <strong>OraSure Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>OraSure Technologies</strong> 的提醒：</p>
</div><p>Here are the key takeaways from OraSure Technologies' conference call:</p>
<div class="lb-trans"><p>以下是 OraSure Technologies 电话会议的关键要点：</p>
</div><ul>
<li>Submitted two FDA applications in December for a rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock) and the <strong>Colli‑Pee</strong> at‑home urine collection device, targeting mid‑year launches and a revenue ramp in H2 2026; management cites a CT/NG TAM of &gt;$1.5 billion.</li>
<li>International diagnostics trends are stabilizing and OTI is pursuing <strong>nearshoring</strong> (in‑country assembly in Africa) and integrating BioMedomics to expand distribution of the <strong>Sickle SCAN</strong> test, with revenue contributions expected beginning in Q1 and through 2026.</li>
<li>Q4 revenue was $26.8M (core $26.7M) above midpoint guidance and GAAP gross margin improved to 41%; the company ended 2025 with $199M cash, zero debt and $15M of buybacks, but reported a GAAP operating loss of $20.1M and negative operating cash flow, guiding Q1 revenue of $26–29M and expecting operating cash flow breakeven by 2027.</li>
<li>Operational actions—manufacturing consolidation to Bethlehem, internalizing contract volumes, and an expected decline in R&amp;D as clinical trials wind down—should drive sequential gross margin improvement as capacity utilization increases with revenue growth.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月提交了两个 FDA 申请，针对衣原体/淋病的快速分子 OTC 自测（Sherlock）和 <strong>Colli-Pee</strong> 家庭尿液采集设备，目标是在年中推出，并在 2026 年下半年实现收入增长；管理层提到 CT/NG 的市场总值超过 15 亿美元。</li>
<li>国际诊断趋势正在稳定，OTI 正在追求 <strong>近岸外包</strong>（在非洲本地组装）并整合 BioMedomics，以扩大 <strong>Sickle SCAN</strong> 测试的分销，预计从第一季度开始贡献收入，并持续到 2026 年。</li>
<li>第四季度收入为 2680 万美元（核心收入 2670 万美元），高于中间指导，GAAP 毛利率改善至 41%；公司在 2025 年结束时现金为 1.99 亿美元，无债务，回购 1500 万美元，但报告 GAAP 营业亏损为 2010 万美元，经营现金流为负，预计第一季度收入为 2600 万至 2900 万美元，并预计到 2027 年实现经营现金流持平。</li>
<li>运营措施——制造整合到贝塞勒姆，内部化合同量，以及随着临床试验结束研发支出的预期下降——应推动随着收入增长而提高的顺序毛利率。</li>
</ul>
</div><h2>OraSure Technologies Price Performance</h2>
<div class="lb-trans"><h2>OraSure Technologies 价格表现</h2>
</div><p>NASDAQ OSUR traded down $0.02 during mid-day trading on Wednesday, reaching $2.80. The stock had a trading volume of 539,717 shares, compared to its average volume of 505,879. The stock has a market cap of $200.84 million, a PE ratio of -3.50 and a beta of 0.87. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.22. The company has a fifty day moving average price of $2.65 and a 200 day moving average price of $2.79.</p>
<div class="lb-trans"><p>周三中午交易时，纳斯达克 OSUR 下跌 0.02 美元，达到 2.80 美元。该股票的交易量为 539,717 股，而其平均交易量为 505,879 股。该公司的市值为 2.0084 亿美元，市盈率为-3.50，贝塔值为 0.87。OraSure Technologies 的 1 年最低价为 2.08 美元，1 年最高价为 4.22 美元。该公司的 50 日移动平均价格为 2.65 美元，200 日移动平均价格为 2.79 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its stake in OraSure Technologies by 12,890.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 49,755 shares of the medical instruments supplier's stock valued at $120,000 after acquiring an additional 49,372 shares during the period. Russell Investments Group Ltd. grew its stake in shares of OraSure Technologies by 13.3% in the fourth quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier's stock worth $106,000 after acquiring an additional 5,138 shares during the period. Sei Investments Co. raised its holdings in shares of OraSure Technologies by 16.4% during the third quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier's stock valued at $103,000 after purchasing an additional 4,536 shares during the last quarter. Numerai GP LLC purchased a new position in shares of OraSure Technologies during the fourth quarter valued at approximately $100,000. Finally, Envestnet Asset Management Inc. lifted its position in OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 8,133 shares during the period. Hedge funds and other institutional investors own 93.50% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该公司的持股。西北互助财富管理公司在第四季度将其在 OraSure Technologies 的股份提高了 12,890.9%。西北互助财富管理公司现在拥有 49,755 股该医疗仪器供应商的股票，价值 120,000 美元，此前在此期间又收购了 49,372 股。拉塞尔投资集团在第四季度将其在 OraSure Technologies 的股份增加了 13.3%。拉塞尔投资集团现在拥有 43,636 股该医疗仪器供应商的股票，价值 106,000 美元，此前在此期间又收购了 5,138 股。Sei Investments Co.在第三季度将其在 OraSure Technologies 的股份提高了 16.4%。Sei Investments Co.现在拥有 32,244 股该医疗仪器供应商的股票，价值 103,000 美元，此前在上个季度又购买了 4,536 股。Numerai GP LLC 在第四季度购买了 OraSure Technologies 的新头寸，价值约 100,000 美元。最后，Envestnet 资产管理公司在第二季度将其在 OraSure Technologies 的持股提高了 32.7%。Envestnet 资产管理公司现在拥有 33,018 股该医疗仪器供应商的股票，价值 99,000 美元，此前在此期间又购买了 8,133 股。对冲基金和其他机构投资者持有该公司 93.50% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages have weighed in on OSUR. Stephens decreased their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an &#34;equal weight&#34; rating for the company in a research note on Wednesday, November 12th. Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OraSure Technologies currently has a consensus rating of &#34;Reduce&#34; and an average price target of $3.00.</p>
<div class="lb-trans"><p>一些券商对 OSUR 发表了看法。斯蒂芬斯在 11 月 12 日的研究报告中将 OraSure Technologies 的目标股价从 3.50 美元下调至 3.00 美元，并对该公司设定了 “持平” 评级。韦斯评级在 1 月 22 日的研究报告中重申了对 OraSure Technologies 的 “卖出（d）” 评级。两位分析师对该股票给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，OraSure Technologies 目前的共识评级为 “减持”，平均目标价为 3.00 美元。</p>
</div><p><strong>View Our Latest Report on OSUR</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 OSUR 的最新报告</strong></p>
</div><h2>OraSure Technologies Company Profile</h2>
<div class="lb-trans"><h2>OraSure Technologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.</p>
<div class="lb-trans"><p>OraSure Technologies, Inc 是一家位于宾夕法尼亚州贝塞勒姆的诊断和医疗设备公司，专注于开发、制造和商业化即时检测和自我检测产品。成立于 1988 年，OraSure 建立了一系列口腔液体和其他非侵入性样本采集技术，支持传染病、药物滥用和健康与保健生物标志物的检测。</p>
</div><p>The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.</p>
<div class="lb-trans"><p>该公司的旗舰产品 OraQuick®快速 HIV 测试是首个获得食品和药物管理局批准的非处方口腔液体 HIV-1/2 抗体检测。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than OraSure Technologies</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>This makes me furious</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 OraSure Technologies</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>这让我感到愤怒</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1NVUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OSUR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OraSure Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 OraSure Technologies 吗？</h2>
</div><p>Before you consider OraSure Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 OraSure Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 OraSure Technologies 并不在名单上。</p>
</div><p>While OraSure Technologies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OraSure Technologies 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

奥瑞许科技（NASDAQ:OSUR）公布了财报，收益每股比预期低 0.04 美元